This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neuhaus, K.-L. Search for Related Content PubMed PubMed Citation Articles by Neuhaus, K.-L.

(Circulation. 1995;92:2794-2795.)
© 1995 American Heart Association, Inc.

Articles

More on Thrombolysis and Hemorrhagic Stroke

Karl-Ludwig Neuhaus, MD

From the Medizinische Klinik II, Städtische Kliniken Kassel, Germany.

Correspondence to Prof Dr Karl-Ludwig Neuhaus, Städtische Kliniken Kassel, Medizinische Klinik II, Mönchebergstr 41-43, D-34125 Kassel, Germany.

Key Words: thrombolysis • stroke • bleeding • Editorials

	Introduction

 
Bleeding complications, including catastrophic intracranial hemorrhage, have always been the inevitable downside of thrombolytic therapy. When the concept of early reperfusion was introduced into the therapy of acute myocardial infarction,^{1 2} previous intravenous thrombolytic regimens were drastically shortened to a 1-hour high-dose infusion, not only to increase efficacy but also to reduce bleeding risks.^{3 4} From subsequent large-scale trials,^{5 6} however, a persistent significant hazard of intracranial hemorrhage was observed. With the advent of the more fibrin-specific thrombolytic tissue-type plasminogen activator (TPA) along with an improved efficacy, a lower bleeding risk was anticipated. Again, the incidence of hemorrhagic strokes turned out to be even higher with the new drug than with streptokinase.^{7 8 9} We still do not know whether TPA is just not sufficiently fibrin specific or whether fibrin specificity per se does not help to reduce the bleeding risk. The answer will be given in the near future by new, completely fibrin-specific thrombolytics such as staphylokinase¹⁰ or TNK, a mutant of wild-type TPA,¹¹ which currently are being investigated in phase II clinical trials.

With currently available drugs, thrombolytic therapy saves about 30 lives per 1000 patients with acute myocardial infarction presenting with ST-segment elevation or bundle-branch block. About 3 of those 1000 patients, however, will die, and another 1 or 2 will suffer a disabling hemorrhagic stroke from thrombolysis.¹²

In an outstanding effort, the GUSTO investigators have provided more detailed information on incidence, category, and outcome of stroke after thrombolysis. They systematically evaluated all the strokes in a 40 000–patient trial on thrombolysis . . . [Full Text of this Article]

This article has been cited by other articles:

				R. L White Thrombolytic Therapy in Acute Myocardial Infarction Part II: 1997 Update Asian Cardiovasc Thorac Ann, March 1, 1998; 6(1): 03 - 10. [Abstract] [Full Text] [PDF]

				How Bad Is Stroke after Thrombolytic Therapy? Journal Watch Dermatology, January 1, 1996; 1996(101): 13 - 13. [Full Text]

				HOW BAD IS STROKE AFTER THROMBOLYTIC THERAPY? Journal Watch (General), December 1, 1995; 1995(1201): 4 - 4. [Full Text]